ArteraAI is a US-based medical artificial intelligence (AI) start-up that develops AI tests that personalize therapy for cancer patients. Artera's flagship test, the ArteraAI Prostate Cancer Test, is in the US National Comprehensive Cancer Network (NCCN) Guidelines, it is reimbursed by Medicare, and it has been adopted by some 20% of all US-based prostate cancer clinicians as of Q2 2025. Artera sells a software platform, which will contain a suite of AI tests across all cancers, and is available internationally. The company was founded in 2021, it has raised $110 million from top-tier investors, it has published over 40 pieces of scientific evidence across all cancers, and it was awarded the TIME Best Invention Award of 2024.